We are developing first-in-class, oral, small molecule drugs that:
1) Target a gene mutation found in over 80% of colorectal cancer patients, and
2) Remyelinate nerve cells in multiple sclerosis (MS)

We’ve already seen unprecedented activity in animal colon cancer models leveraging synthetic lethality, without toxicity. And we have a clear development strategy to reach human proof of concept in Colorectal Cancer in 2022 and human proof of concept in Demyelinating Diseases in 2022-2023.


people a year die from
colorectal cancer in the US.


Colorectal cancer is the 3rd leading cause of cancer deaths worldwide.


worldwide market.

Despite newer therapies such as EGFR, VEGF inhibitors & immuno-oncology agents, CRC remains a deadly disease with ~50,000 deaths annually in the US alone. With the need for newer treatment options in this patient population, the worldwide market opportunity is ~$10 Billion.

Our Drug Platforms:
TASIN in Oncology & Neurology

TASIN in Colorectal Cancer is lethal for mutated APC cancer cells, while having virtually no effect on normal cells.

TASIN in Neurology directly binds and inhibits a target gaining much interest in the pharma industry, emopamil binding protein (EBP), which results in the formation of myelin around nerve cells.

TASIN has shown to be highly potent, resulting in significant inhibition of CRC tumor growth, with no apparent toxicity to normal cells.

We have fantastic binding data between TASIN and EBP which has been confirmed using multiple approaches including use of CRISPR technology.

"We expect TASIN for CRC to be in the clinic in 2021, with human proof of concept in 2022. There are also some very interesting opportunities for TASIN in de-myelinating diseases — such as multiple sclerosis (MS), and we plan to have proof-of-concept data in a gold standard MS animal model by early Q4 2020. We’re currently seeking investors to reach a key value inflection point."

Neil Thapar

CEO & Chief Scientific Officer